全文获取类型
收费全文 | 21215篇 |
免费 | 1578篇 |
国内免费 | 701篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 220篇 |
妇产科学 | 142篇 |
基础医学 | 862篇 |
口腔科学 | 140篇 |
临床医学 | 1525篇 |
内科学 | 2562篇 |
皮肤病学 | 276篇 |
神经病学 | 2123篇 |
特种医学 | 200篇 |
外国民族医学 | 1篇 |
外科学 | 755篇 |
综合类 | 2275篇 |
一般理论 | 3篇 |
预防医学 | 1200篇 |
眼科学 | 155篇 |
药学 | 9053篇 |
7篇 | |
中国医学 | 1269篇 |
肿瘤学 | 686篇 |
出版年
2024年 | 65篇 |
2023年 | 338篇 |
2022年 | 493篇 |
2021年 | 712篇 |
2020年 | 703篇 |
2019年 | 781篇 |
2018年 | 781篇 |
2017年 | 846篇 |
2016年 | 748篇 |
2015年 | 735篇 |
2014年 | 1475篇 |
2013年 | 2259篇 |
2012年 | 1340篇 |
2011年 | 1417篇 |
2010年 | 1125篇 |
2009年 | 943篇 |
2008年 | 901篇 |
2007年 | 929篇 |
2006年 | 764篇 |
2005年 | 684篇 |
2004年 | 570篇 |
2003年 | 551篇 |
2002年 | 400篇 |
2001年 | 380篇 |
2000年 | 297篇 |
1999年 | 263篇 |
1998年 | 240篇 |
1997年 | 221篇 |
1996年 | 215篇 |
1995年 | 194篇 |
1994年 | 162篇 |
1993年 | 190篇 |
1992年 | 185篇 |
1991年 | 141篇 |
1990年 | 132篇 |
1989年 | 109篇 |
1988年 | 119篇 |
1987年 | 76篇 |
1986年 | 89篇 |
1985年 | 129篇 |
1984年 | 117篇 |
1983年 | 82篇 |
1982年 | 94篇 |
1981年 | 61篇 |
1980年 | 72篇 |
1979年 | 56篇 |
1978年 | 64篇 |
1977年 | 59篇 |
1976年 | 47篇 |
1975年 | 45篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
It is hypothesized that persons who use drugs (PWUD) in Vietnam who are also HIV-positive may face additional challenges in psychosocial outcomes, and these challenges may extend to their family members. In this study, we examined depressive symptoms, stigma, social support, and caregiver burden of HIV-positive PWUD and their family members, compared to the outcomes of HIV-negative PWUD and their family members. Baseline, 3-month, and 6-month assessment data were gathered from 83 PWUD and 83 family members recruited from four communes in Phú Th? Province, Vietnam. For PWUD, although we observed a general decline in overall stigma over time for both groups, HIV-positive PWUD consistently reported significantly higher overall stigma for all three periods. Depressive symptoms among family members in both groups declined over time; however, family members of HIV-positive PWUD reported higher depressive symptoms across all three periods. In addition, family members of HIV-positive PWUD reported lower levels of tangible support across all three periods. Caregiver burden among family members of HIV-positive PWUD increased significantly over time, whereas the reported burden among family members of HIV-negative PWUD remained relatively unchanged. The findings highlight the need for future interventions for PWUD and family members, with targeted and culturally specific strategies to focus on the importance of addressing additional stigma experienced by PWUD who are HIV-positive. Such challenges may have direct negative impact on their family members' depressive symptoms, tangible support, and caregiver burden. 相似文献
2.
3.
4.
目的 了解解放军总医院抗震颤麻痹药物的应用情况与用药趋势。方法 采用世界卫生组织(WHO)推荐的以限定日剂量(DDD)为指标的分析方法,对2015-2017年解放军总医院抗震颤麻痹药物的销售金额、用药频度(DDDs)、日均费用(DDC)及排序比(B/A)等进行统计分析。结果 普拉克索、多巴丝肼和恩他卡朋的用药金额始终处于前3位,普拉克索的用药金额逐渐上升,卡比多巴/左旋多巴的用药金额逐渐下降;DDDs排序列前2位的是多巴丝肼和司来吉兰,多巴丝肼的DDDs逐年上升,一直处于第1位;2015-2016年各种抗震颤麻痹药物的DDC较为稳定,2016-2017年各种抗震颤麻痹药物的DDC开始略有下降;除普拉克索和恩他卡朋的B/A始终小于1.00,其他抗震颤麻痹药物的B/A均在1.00以上波动。结论 解放军总医院抗震颤麻痹药物的使用较为合理,其中多巴丝肼、普拉克索和司来吉兰具有很好的市场前景。 相似文献
5.
6.
7.
The toxic effects of nitroquine-dapsone compound(NQD)in mice and dogs were studied.The therapeutic index of NQDin mice is 1911,the greatest among the 6 antimalarials tested.Thetoxic effects of NQD(50 mg/kg/day for 3 days per os)and nitro-quine in dogs were manifested by injuries on the adrenal cortexand intestinal epithelium.When folic acid(4 mg/kg/day for 4 days)or calcium leucovorinum(0.3 mg/kg/day for 4 days)were usedconcomitantly with NQD,the death rate and the incidence of dia-rrhea in the toxicated dogs were greatly reduced,the injury on theintestinal epithelium was much milder,and the goblet cells weremuch more numerous than those without treatment.The results suggestthat folic acid and calcium leucovorinum can protect the undifferen-tiated cells in the intestinal crypts from being injured by NQD. 相似文献
8.
Robert M. Levy Roman Saikovsky Evgeniya Shmidt Alexander Khokhlov Bruce P. Burnett 《Nutrition Research》2009
Flavocoxid (Limbrel), a proprietary mixture of flavonoid molecules (baicalin and catechin), was tested against a traditional nonsteroidal anti-inflammatory drug, naproxen, for the management of the signs and symptoms of moderate osteoarthritis (OA) in humans. Discomfort and global disease activity were used as the primary end points, and safety assessments were also taken for both treatments as a secondary endpoint. In this double-blind study, 103 subjects were randomly assigned to receive either flavocoxid [500 mg twice daily (BID)] or naproxen (500 mg BID) in a 1-month onset of action trial. Outcome measures included the short Western Ontario and McMaster University Osteoarthritis Index, subject Visual Analogue Scale for discomfort and global response, and investigator Visual Analogue Scale for global response and fecal occult blood. Both flavocoxid and naproxen showed significant reduction in the signs and symptoms of knee OA (P ≤ .001). There were no statistically detectable differences between the flavocoxid and naproxen groups with respect to any of the outcome variables. Similarly, there were no statistically detectable differences between the groups with respect to any adverse event, although there was a trend toward a higher incidence of edema and nonspecific musculoskeletal discomfort in the naproxen group. In this short-term pilot study, flavocoxid was as effective as naproxen in controlling the signs and symptoms of OA of the knee and would present a safe and effective option for those individuals on traditional nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors. A low incidence of adverse events was reported for both groups. 相似文献
9.
W A Turski M Dziki E Urbanska L S Calderazzo-Filho E A Cavalheiro 《Synapse (New York, N.Y.)》1991,7(3):173-180
Systemic (s.c.) administration of aminooxyacetic acid (AOAA) in mice triggered clonic convulsions with a CD50 (convulsive dose) of 68 mg/kg (range 54-86). AOAA also induced clonic convulsions in mice subjected to intracerebroventricular administration of the drug with a CD50 of 0.04 mumols (range 0.028-0.06). At the onset of convulsions induced by systemic AOAA (CD97;150 mg/kg), the GAD activity in the frontal cortex and hippocampus was not affected. GABA mimetic drugs, progabide and gabaculine, had no effect on convulsions induced by AOAA. Convulsions induced by systemic administration of AOAA were blocked by diazepam, phenobarbital, and valproate. Ethosuximide, trimethadione, acetazolamide, diphenylhydantoin, and carbamazepine remained ineffective. L-Phenylisopropyladenosine was also found to protect mice against AOAA-induced convulsions, whereas atropine and baclofen had no effect. The seizures induced by intracerebroventricular administration of AOAA (CD97; 0.1 mumols) were blocked by coadministration of preferential N-methyl-D-aspartate antagonists, D-(-)-2-aminophosphonoheptanoic (AP7), 3-[+/-)-2-carboxypiperazine-4-yl)-propyl-1-phosphonic (CPP), and kynurenic acid (KYNA); preferential quisqualate/kainate antagonists, 6-cyano-7-nitro-quinoxaline-2,3-dione and gamma-D-glutamylaminomethylsulphonic acid, remained inactive in the range of dosages sufficient to block seizures induced by quisqualic acid or kainic acid. The antagonistic action of antiepileptic drugs effective against seizures induced by excitatory amino acids (diazepam and valproate), and drugs acting on excitatory amino acid receptors (AP7, CPP, and KYNA) upon seizures induced by AOAA suggests an involvement of excitatory neurotransmission in the convulsant action of the drug. 相似文献
10.
Despite the use of gold complexes in modern medicine for over 100 years and the use of gold complexes in the management of
rheumatoid disease for more than 60 years, the definitive mechanisms of action for efficacy and for toxicity have not been
established.
Gold is a group 1b metal in the periodic table with several oxidation states but it is only Au(I) which is active in the biological
milieu. Gold sodium thiomalate is not only a polymeric structure, but also has the chiral ligand, thiomalic acid. Gold sodium
thiomalate thus can exist in several different physical states which may have different biological activity. In addition the
pharmacokinetic profile of gold complexes has been of little value in the understanding of either the mechanism of action,
efficacy or toxicity for both the injectable and the oral gold complexes. Many authors have misinterpreted research data on
the activities of gold complexes because they compared gold complexes of different structures, and gold complexes which exist
at different pH.
Experimental work in our laboratory has identified that gold sodium thiomalate is a mixture and can exist as either a yellow
or a colourless solution. These have some similar but several different biological activities.
Many factors contribute to the lack of understanding of the action of gold complexes. Some of these factors are related to
the wide variation in physical structure and biological activities exhibited by these compounds. 相似文献